Reasons for Response Differences Seen in the V15-32, INTEREST and IPASS Trials

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2009 Apr 25

PMID 19390555

Citations 7

Authors

Nagahiro Saijo

Masahiro Takeuchi

Hideo Kunitoh

Affiliations

Soon will be listed here.

Abstract

The first phase III study to assess the effect of gefitinib and docetaxel on the survival of Japanese patients with non-small-cell lung cancer who received previous treatment with platinum doublets, the V15-32 trial, did not establish noninferiority of gefitinib over docetaxel in terms of the effect on overall survival, despite the results showing a twofold higher response rate to gefitinib. The overall survival favored docetaxel for the first 18 months and gefitinib thereafter. The INTEREST trial, which compared docetaxel and gefitinib, demonstrated noninferiority of gefitinib, and the survival curves were completely superimposed. In this trial, patients had been recruited from 24 countries from Europe, Asia, and North and South America. Results of the IPASS trial showed superior progression-free survival for gefitinib compared with the combination of carboplatin and paclitaxel as first-line treatment in Asian patients who were nonsmokers and had adenocarcinoma histology. In this Review, we discuss the reasons for the differences in the effects of molecular-targeted drugs and cytotoxic antineoplastic agents observed in these trials. We also highlight the magnitude of the antitumor activity of these two different categories of drugs, and discuss how this could affect future clinical trial design and analysis.

Citing Articles

DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: a retrospective Chinese cohort study.

Xiao Z, Sun L, Zheng Y, Chen H, Zheng X, Luo J Transl Lung Cancer Res. 2023; 11(12):2539-2566.

PMID: 36636408 PMC: 9830265. DOI: 10.21037/tlcr-22-746.

Prognostic and predictive value of serum carcinoembryonic antigen levels in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutations and receiving tyrosine kinase inhibitors.

Zhao X, Zhao J, Xing K, Sun S, Luo Z, Wang H Oncotarget. 2017; 8(41):70865-70873.

PMID: 29050327 PMC: 5642602. DOI: 10.18632/oncotarget.20145.

The level of serum carcinoembryonic antigen is a surrogate marker for the efficacy of EGFR-TKIs but is not an indication of acquired resistance to EGFR-TKIs in NSCLC patients with EGFR mutationsm.

Han J, Li Y, Cao S, Dong Q, Zhao G, Zhang X Biomed Rep. 2017; 7(1):61-66.

PMID: 28685062 PMC: 5492672. DOI: 10.3892/br.2017.914.

Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions.

Hsu P, Chiu L, Li S, Chen C, Wang C, Kao K Biomed J. 2016; 39(2):121-9.

PMID: 27372167 PMC: 6140297. DOI: 10.1016/j.bj.2015.07.002.

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).

Shi Y, Au J, Thongprasert S, Srinivasan S, Tsai C, Khoa M J Thorac Oncol. 2014; 9(2):154-62.

PMID: 24419411 PMC: 4132036. DOI: 10.1097/JTO.0000000000000033.

References

Chang A, Parikh P, Thongprasert S, Tan E, Perng R, Ganzon D . Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol. 2007; 1(8):847-55. View

Hynes N, Lane H . ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5(5):341-54. DOI: 10.1038/nrc1609. View

Kelly K, Crowley J, Bunn Jr P, Presant C, Grevstad P, Moinpour C . Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001; 19(13):3210-8. DOI: 10.1200/JCO.2001.19.13.3210. View

Yarden Y, Sliwkowski M . Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2(2):127-37. DOI: 10.1038/35052073. View

Saijo N . Recent trends in the treatment of advanced lung cancer. Cancer Sci. 2006; 97(6):448-52. PMC: 11159014. DOI: 10.1111/j.1349-7006.2006.00198.x. View

Schiller J, Harrington D, Belani C, Langer C, Sandler A, Krook J . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346(2):92-8. DOI: 10.1056/NEJMoa011954. View

Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U . Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005; 23(28):6829-37. DOI: 10.1200/JCO.2005.01.0793. View

Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-500. DOI: 10.1126/science.1099314. View

Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A . EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005; 23(4):857-65. DOI: 10.1200/JCO.2005.08.043. View

10.

Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N . Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol. 2006; 24(21):3340-6. DOI: 10.1200/JCO.2005.05.4692. View

11.

Hirsch F, Varella-Garcia M, McCoy J, West H, Xavier A, Gumerlock P . Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol. 2005; 23(28):6838-45. DOI: 10.1200/JCO.2005.01.2823. View

12.

Kim E, Hirsh V, Mok T, Socinski M, Gervais R, Wu Y . Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008; 372(9652):1809-18. DOI: 10.1016/S0140-6736(08)61758-4. View

13.

Mitsudomi T, Yatabe Y . Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007; 98(12):1817-24. PMC: 11159145. DOI: 10.1111/j.1349-7006.2007.00607.x. View

14.

Shepherd F, Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123-32. DOI: 10.1056/NEJMoa050753. View

15.

Giaccone G, Rodriguez J . EGFR inhibitors: what have we learned from the treatment of lung cancer?. Nat Clin Pract Oncol. 2005; 2(11):554-61. DOI: 10.1038/ncponc0341. View

16.

Herbst R, Maddox A, Rothenberg M, Small E, Rubin E, Baselga J . Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol. 2002; 20(18):3815-25. DOI: 10.1200/JCO.2002.03.038. View

17.

Han S, Kim T, Hwang P, Jeong S, Kim J, Choi I . Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2005; 23(11):2493-501. DOI: 10.1200/JCO.2005.01.388. View

18.

Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J . Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003; 21(12):2237-46. DOI: 10.1200/JCO.2003.10.038. View

19.

Ranson M, Hammond L, Ferry D, Kris M, Tullo A, Murray P . ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 2002; 20(9):2240-50. DOI: 10.1200/JCO.2002.10.112. View

20.

Johnson B, Janne P . Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations?. J Clin Oncol. 2005; 23(28):6813-6. DOI: 10.1200/JCO.2005.97.008. View